靶向前列腺特异性膜抗原药物递送系统对前列腺癌的作用

Prostate-specific membrane antigen-targeted drug delivery system for prostate cancer

前列腺癌(PCa)是男性泌尿生殖系统中最常见的恶性肿瘤,给个人和社会带来巨大负担。基于传统给药模式下的各种治疗手段很难获得令人满意的效果,因此开发创新而有效的给药途径是非常必要的。药物传递系统(DDS)兼具递送和控释特征,被广泛应用于药物递送。前列腺特异性膜抗原(PSMA)是PCa最具特征性和高选择性的生物标志物之一,具有良好的PCa靶向性。目前已经探索了许多靶向PSMA的DDS,包括药物配体结合物和纳米药物递送系统(聚合物纳米粒、无机纳米粒、脂质体和生物性纳米粒等)。本文综述了近年来研究者们对于靶向PSMA的DDS在PCa中的作用的相关研究,以期为PCa的精准、有效治疗提供参考。

Prostate cancer(PCa)is a most common malignancy in the genitourinary system,which imposes a huge burden on the patients and society.Various traditional medication methods fail to achieve satisfactory effects,and therefore it is imperative to develop innovative and effective routes of administration.Drug delivery systems have the characteristics of both delivery and controlled release and are widely used clinically.Prostate-specific membrane antigen(PSMA)is one of the most characteristic and highly selective biomarkers of PCa with a good PCa-targetability.Many drug delivery systems targeting PSMA have been explored,including drug-ligand conjugates and nano-drug delivery systems(polymer nanoparticles,inorganic nanoparticles,liposomes,and biological nanoparticles,etc.).This article reviews the recent studies on the role of the PSMA-targeting drug delivery system in PCa,in order to provide some reference for the precise and effective treatment of the malignancy.